TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02040584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minimisation of TAC
Description: •EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAC + MMF + corticosteroids
Description: •Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
Study: NCT00359216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
Study: NCT03306459

Intervention type: DIAGNOSTIC_TEST
Intervention: SF-36 (Short Form Health Survey)
Description: Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score.

Intervention type: DIAGNOSTIC_TEST
Intervention: SF-36 (Short Form Health Survey)
Description: Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score.
Study: NCT02445001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG loaded erythrocytes
Description: For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
Study: NCT03450187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
Study: NCT03840915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
Study: NCT01416220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
Study: NCT03546686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy/Cryoablation
Description: US-guided core biopsy and cryoablation 7-10 days prior to surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard-of-care definitive surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
Study: NCT04223479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Capsule
Description: The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
Study: NCT04467905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil
Description: The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
Study: NCT04080648

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venapuncture
Description: Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaires
Description: The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
Study: NCT06597084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL 800 mg
Description: 800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Study: NCT03840915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
Study: NCT06601205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 1 tablet daily until the day before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 1 tablet daily until the day before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily until the day before surgery
Study: NCT06597903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL994
Description: In the afternoon/evening before colonoscopy: 1 litre solution plus 0.5 litre clear fluid.~Day of colonoscopy: 1 litre solution plus at least up to 1 litre clear liquid.
Study: NCT06587165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N15-thymidine
Description: 50mg/kg (oral administration)
Study: NCT03840915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
Study: NCT03809559

Intervention type: DEVICE
Intervention: MRCP+
Description: Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.

Intervention type: DEVICE
Intervention: MRCP+
Description: Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.

Intervention type: DEVICE
Intervention: MRCP+
Description: Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
Study: NCT01874431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02367820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-181 BID tablets
Description: NKTR-181 tablets 100-600 mg twice daily (BID)
Study: NCT00710853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YiRen Qi gong
Description: One hour weekly class for 8 week duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: One hour weekly class for 8 week duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hatha yoga
Description: One hour weekly class for 8 week duration
Study: NCT04374344

Intervention type: OTHER
Intervention: Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements
Description: Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
Study: NCT01336803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: 5 mg/kg by intravenous (IV) administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
Study: NCT02470910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study: NCT03211754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: walnuts and almonds
Description: The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
Study: NCT04806542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMR-group
Description: A mindfulness-based 8 week program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Individual counselling.
Study: NCT03170037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard V-E ventilation technique
Description: For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reversal V-E ventilation technique
Description: While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
Study: NCT02778854

Intervention type: GENETIC
Intervention: detection of driver mutation
Description: participants are received gene detection via the liquid biopsy

Intervention type: GENETIC
Intervention: detection of driver mutation
Description: participants are received gene detection via the liquid biopsy
Study: NCT02630693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 100mg
Description: 100mg PO daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: 125mg PO daily 3 weeks out of 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant or Tamoxifen or Aromatase Inhibitor
Description: given at the standard doses/schedules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant or Tamoxifen or Aromatase Inhibitor
Description: given at the standard doses/schedules
Study: NCT03743285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
Study: NCT00822211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03193359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
Study: NCT05314790

Intervention type: OTHER
Intervention: intervening Educational Program
Description: The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
Study: NCT02220673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for RMT-B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for HFA-MDI
Study: NCT02349373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: An 8 week preconditioning period
Description: Receipt of a weekly running schedule through an online training diary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 16 week training period
Description: Receipt of a weekly running schedule through an online training diary.
Study: NCT03010176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulevostinag
Description: IT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion